Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | FLT3 | P36888 | 5/20 | 0.42 |
| ▸ | MDM2 | Q00987 | 3/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.38 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.37 |
| ▸ | TGM2 | P21980 | 1/20 | 0.37 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.36 |
| ▸ | KDR | P35968 | 1/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.35 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.34 |
| ▸ | CDK2 | P24941 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7134441 | 0.85 | MYC (0.43) | MEN1KMT2AFLT3ADORA2AKDR | |
| SCHEMBL7136928 | 0.84 | KMT2A (0.37) | MEN1KMT2AFLT3MDM2ADORA2A | |
| SCHEMBL5362861 | 0.84 | MEN1 (0.46) | MEN1KMT2AFLT3MDM2ALK | |
| SCHEMBL7138200 | 0.84 | MEN1 (0.47) | MEN1KMT2AFLT3MDM2ALK | |
| SCHEMBL5357855 | 0.82 | MEN1 (0.39) | MEN1KMT2AFLT3KDRCCNE1 | |
| SCHEMBL5368774 | 0.80 | MEN1 (0.37) | MEN1KMT2AFLT3MDM2ALK | |
| SCHEMBL5366373 | 0.78 | KDR (0.36) | MEN1KMT2AFLT3PDGFRBKDR | |
| SCHEMBL7139913 | 0.77 | RAF1 (0.42) | MEN1KMT2APDGFRBNTRK1 | |
| SCHEMBL7136994 | 0.77 | MAOA (0.44) | MEN1KMT2AFLT3PDGFRBKDR | |
| SCHEMBL7138309 | 0.76 | MEN1 (0.51) | MEN1KMT2AFLT3MDM2PDGFRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7202265-B2 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | SUGEN, INC. | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050197382-A1 | Indolinone combinatorial libraries and related products and methods for the treatment of disease | FRK, PTK2, DSTYK | MEN1 3855/4885KMT2A 4060/4885FLT3 395/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.